Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Wockhardt announces COVID-19 vaccine partnership with UK Government

Posted On: 2020-08-03 02:11:42


Wockhardt, the global pharmaceutical and biotechnology major today announced that it has entered into an agreement with the UK Government to fill finish COVID-19 vaccines. The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales.

As per the terms of the agreement the company has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID19, including AZD1222, the vaccine co-invented by the University of Oxford and its spinout company, Vaccitech and licensed by AstraZeneca.

Dr Habil Khorakiwala, Founder Chairman of Wockhardt emphasised, "The pandemic of COVID-19 is a challenge for all and needs a concerted effort to overcome. We are proud to be collaborating with the UK Government to make vaccines available and the arrangement brings in a huge sense of purpose and pride, it upholds our ongoing commitment to fight against such a pandemic of global human importance. As a global organisation, we are focussed and committed to assist in mitigating the worldwide impact of COVID-19."

Alok Sharma, Secretary of State for Business, Energy and Industrial Strategy, Government of U.K said, "Ensuring the UK has the capability to research, develop and manufacture a safe and effective vaccine is critical in our fight against coronavirus.

"Today we have secured additional capacity to manufacture millions of doses of multiple Covid-19 candidates, guaranteeing the supply of vaccines we need to protect people across the UK rapidly and in large numbers."

Speaking about the contract Ravi Limaye, Managing Director Wockhardt UK said, "We are immensely proud to have been selected to partner with the UK Government on this project. In doing so we are taking a lead role in the nation's fight against pandemic of COVID-19".

"We have a sophisticated sterile manufacturing facility and a highly skilled workforce. We expect to start delivering the first doses of the vaccine later this year." He added. The government has reserved one fill and finish production line for its exclusive use for the next 18 months in order to guarantee the supply of vaccines required to fight COVID-19 in the UK.

Dr Murtaza Khorakiwala, Managing Director and Global CEO of Wockhardt adds, "The arrangement with the UK Government for manufacturing vaccines for COVID-19 showcases our global strength in world class sterile injectable facilities and capacity. With four decades of expertise and experience behind us we are able to quickly scale to manufacture and assist in mitigating the worldwide impact of COVID-19."

Kate Bingham, Chair of U.K. Vaccines Task Force said, "Never before have we needed to find and manufacture a vaccine at this speed and scale in order to protect the UK population. We have made significant progress in securing a diverse portfolio of potential vaccines and treatments for Covid-19, adding a fourth vaccine candidate from GSK and Sanofi last week. However, discovering a successful vaccine is only part of the solution, we also need to be able to manufacture it. Fill Finish is a critical step in the process to get the vaccine in a form to be given to patients. The agreement with Wockhardt will boost our capability to ensure that from the moment a successful vaccine is identified we will be able to produce the quantities of vaccine required, as quickly as possible, for the people who need it."

Wockhardt is a global pharmaceutical and biotech organisation that brings affordable, high quality medicines to market. In the UK, Wockhardt is one of the largest suppliers into the NHS for over 20 years, has had a presence in Wrexham for over two decades and employs over 400 people at its 612,000 square feet high-tech manufacturing facility.

Shares of WOCKHARDT LTD. was last trading in BSE at Rs.275.85 as compared to the previous close of Rs. 262.9. The total number of shares traded during the day was 215308 in over 4892 trades.

The stock hit an intraday high of Rs. 281.55 and intraday low of 261.15. The net turnover during the day was Rs. 59114524.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Zydus Wellness Limited fixes Rs. 1775.85 as floor price for QIP

Baring Private Equity Asia to delist Hexaware Technologies Limited from the Stock Exchanges in India

IDFC FIRST Bank to launch SafePay - contactless card payments on phone

Kirloskar Brothers Ltd invests Rs. 7.50 crore in The Kolhapur Steel Ltd

Datamatics announces expansion of distribution agreement with Ingram Micro for META region for its Intelligent Automation (IA) products

K P I Global Infrastructure Ltd completes development of new 11kV transmission line

IIFL Securities Ltd to acquire additional 6.25% stake in Trendlyne

TCS and Yale University Develop Secure, Private Off-Grid Networking Platform Using Blockchain

ICRA removes rating watch on JSPL's bank facilities

STL strengthens global leadership team to drive the next phase of growth

Mphasis partners with fintech platform Upswot to offer marketing insights though alternative data for business banking

HCG - Strand Life Sciences Launch StrandAdvantage500 to Broaden Patient Access to Genomic Testing

GAIL wins Leaders Award at the Frost & Sullivan and TERI's Sustainability 4.0 Awards 2020

Aurionpro announces Smart Transit wins in Global Markets

Ircon International Ltd secures works for Rs. 400 crore

CreditAccess Grameen Ltd allots 1000 NCDs

WABCO India Ltd board to consider quarterly results on Oct 23, 2020

Hexaware's Unified Teams Bot COCO is Now Available on Microsoft AppSource

Airtel onboards Waybeo to its Startup Accelerator Program

StackRoute announces programs in Data Engineering to meet the Enterprise Big Data requirement of the industry

Hester acquires technology from ICAR - IVRI to develop a new generation Brucella Abortus S19 Delta Per Vaccine

Tech Mahindra and Rakuten Mobile Collaborate to Bring RCP to Global Customers

TCS OmniStore™ Wins Award for Excellence in Omnichannel Interactive Customer Experience

Palash Aggrawal joins LT Foods as Group Head HR

IndiGo tops the Safe Travel Barometer in India

BEML Ltd raises Rs. 150 crores through Commercial Paper

SRL Diagnostics extends its collaborative endeavors for AI in Histopathology

Mphasis is a leading Machine Learning (ML) solutions partner in AWS Marketplace

Discovered price of Rs. 475 accepted as delisting offer price of Hexaware Technologies Ltd

Bajaj Holdings & Investment Ltd Board to consider Q2 results on October 22, 2020

Maharashtra Scooters Ltd Board to consider Q2 results on October 20, 2020

Global investment firm KKR to invest ₹ 5,550 crore in Reliance Retail Ventures

Sun Pharma announces the launch of ILUMYA® (tildrakizumab) for treatment of Plaque Psoriasis in Japan

Satin Creditcare Network Ltd to consider NCD issue to raise Rs. 175 crore

IndiGo operated its maiden CarGo flight to Chittagong

TCS Deploys AI-Powered Software to Enable Safe Return to Work for its Employees

Lupin Launches Divalproex Sodium ER Tablets USP

HCC closes sale of Farakka Raiganj Highways to Cube Highways at enterprise value of Rs. 1,508 Crore

CG-VAK Software and Exports Limited awarded Endurance Award by CII

Maan Aluminium Ltd recognised as 'Two Star Export House'

TTK Prestige Ltd board to consider 2nd quarter results on Nov 10, 2020

Federal Bank Offers EMI on Debit Cards to Customers for Purchase of Two Wheelers

GE to pursue exit from new build coal power market

Wonderla Holidays Ltd. Launches

Fitch takes rating action on Four Indian NBFIs following pandemic-impact review

ANUH Pharma Ltd approves allotment of 2,50,56,000 Equity Shares

Morrisons Expands Strategic Partnership with TCS

CRISIL reaffirms commercial paper rating of Cadila Healthcare Ltd

Strides receives USFDA approval for Butalbital, Acetaminophen, and Caffeine Tablets

Kavit Industries Limited to acquire existing pharma company, change name







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019